Update on emerging biomarkers in lung cancer

Eric H. Bernicker; Timothy Craig Allen; Phillip T. Cagle

doi:10.21037/jtd.2019.01.46

Update on emerging biomarkers in lung cancer

Eric H. Bernicker, Timothy Craig Allen, Phillip T. Cagle

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.

Original language	English (US)
Pages (from-to)	S81-S88
Journal	Journal of Thoracic Disease
Volume	11
Issue number	Suppl 1
DOIs	https://doi.org/10.21037/jtd.2019.01.46
State	Published - Jan 1 2019

Keywords

Anaplastic lymphoma kinase (ALK)
BRAF
Biomarkers
Epidermal growth factor receptor (EGFR)
MET
RET
Tumor mutational burden

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.21037/jtd.2019.01.46

Cite this

@article{204b2a7528784c0a929c9f5c3005dd19,

title = "Update on emerging biomarkers in lung cancer",

abstract = "There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.",

keywords = "Anaplastic lymphoma kinase (ALK), BRAF, Biomarkers, Epidermal growth factor receptor (EGFR), MET, RET, Tumor mutational burden",

author = "Bernicker, {Eric H.} and Allen, {Timothy Craig} and Cagle, {Phillip T.}",

year = "2019",

month = jan,

day = "1",

doi = "10.21037/jtd.2019.01.46",

language = "English (US)",

volume = "11",

pages = "S81--S88",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

publisher = "Pioneer Bioscience Publishing Company (PBPC)",

number = "Suppl 1",

}

TY - JOUR

T1 - Update on emerging biomarkers in lung cancer

AU - Bernicker, Eric H.

AU - Allen, Timothy Craig

AU - Cagle, Phillip T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.

AB - There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.

KW - Anaplastic lymphoma kinase (ALK)

KW - BRAF

KW - Biomarkers

KW - Epidermal growth factor receptor (EGFR)

KW - MET

KW - RET

KW - Tumor mutational burden

UR - http://www.scopus.com/inward/record.url?scp=85061152085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061152085&partnerID=8YFLogxK

U2 - 10.21037/jtd.2019.01.46

DO - 10.21037/jtd.2019.01.46

M3 - Review article

C2 - 30775031

AN - SCOPUS:85061152085

SN - 2072-1439

VL - 11

SP - S81-S88

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

IS - Suppl 1

ER -

Update on emerging biomarkers in lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this